Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.


The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page


My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2004 2
2005 5
2006 6
2007 3
2008 4
2009 2
2010 2
2011 3
2012 4
2013 4
2014 2
2015 8
2016 5
2017 16
2018 12
2019 19
2020 19
2021 25
2022 20
2023 26
2024 8

Text availability

Article attribute

Article type

Publication date

Search Results

166 results

Results by year

Filters applied: . Clear all
Page 1
Olutasidenib (FT-2102) in patients with relapsed or refractory IDH1-mutant glioma: A multicenter, open-label, phase Ib/II trial.
de la Fuente MI, Colman H, Rosenthal M, Van Tine BA, Levacic D, Walbert T, Gan HK, Vieito M, Milhem MM, Lipford K, Forsyth S, Guichard SM, Mikhailov Y, Sedkov A, Brevard J, Kelly PF, Mohamed H, Monga V. de la Fuente MI, et al. Among authors: monga v. Neuro Oncol. 2023 Jan 5;25(1):146-156. doi: 10.1093/neuonc/noac139. Neuro Oncol. 2023. PMID: 35639513 Free PMC article. Clinical Trial.
Boron in cancer therapeutics: An overview.
Kulkarni S, Bhandary D, Singh Y, Monga V, Thareja S. Kulkarni S, et al. Among authors: monga v. Pharmacol Ther. 2023 Nov;251:108548. doi: 10.1016/j.pharmthera.2023.108548. Epub 2023 Oct 17. Pharmacol Ther. 2023. PMID: 37858628 Review.
Pharmacological ascorbate as a novel therapeutic strategy to enhance cancer immunotherapy.
Zaher A, Stephens LM, Miller AM, Hartwig SM, Stolwijk JM, Petronek MS, Zacharias ZR, Wadas TJ, Monga V, Cullen JJ, Furqan M, Houtman JCD, Varga SM, Spitz DR, Allen BG. Zaher A, et al. Among authors: monga v. Front Immunol. 2022 Aug 22;13:989000. doi: 10.3389/fimmu.2022.989000. eCollection 2022. Front Immunol. 2022. PMID: 36072595 Free PMC article. Review.
Radiology Gets Chatty: The ChatGPT Saga Unfolds.
Grewal H, Dhillon G, Monga V, Sharma P, Buddhavarapu VS, Sidhu G, Kashyap R. Grewal H, et al. Among authors: monga v. Cureus. 2023 Jun 8;15(6):e40135. doi: 10.7759/cureus.40135. eCollection 2023 Jun. Cureus. 2023. PMID: 37425598 Free PMC article.
CDK4/6-MEK Inhibition in MPNSTs Causes Plasma Cell Infiltration, Sensitization to PD-L1 Blockade, and Tumor Regression.
Kohlmeyer JL, Lingo JJ, Kaemmer CA, Scherer A, Warrier A, Voigt E, Raygoza Garay JA, McGivney GR, Brockman QR, Tang A, Calizo A, Pollard K, Zhang X, Hirbe AC, Pratilas CA, Leidinger M, Breheny P, Chimenti MS, Sieren JC, Monga V, Tanas MR, Meyerholz DK, Darbro BW, Dodd RD, Quelle DE. Kohlmeyer JL, et al. Among authors: monga v. Clin Cancer Res. 2023 Sep 1;29(17):3484-3497. doi: 10.1158/1078-0432.CCR-23-0749. Clin Cancer Res. 2023. PMID: 37410426 Free PMC article.
Radioresistance in Glioblastoma and the Development of Radiosensitizers.
Ali MY, Oliva CR, Noman ASM, Allen BG, Goswami PC, Zakharia Y, Monga V, Spitz DR, Buatti JM, Griguer CE. Ali MY, et al. Among authors: monga v. Cancers (Basel). 2020 Sep 3;12(9):2511. doi: 10.3390/cancers12092511. Cancers (Basel). 2020. PMID: 32899427 Free PMC article. Review.
Turning 'Cold' tumors 'Hot': immunotherapies in sarcoma.
Rytlewski J, Milhem MM, Monga V. Rytlewski J, et al. Among authors: monga v. Ann Transl Med. 2021 Jun;9(12):1039. doi: 10.21037/atm-20-6041. Ann Transl Med. 2021. PMID: 34277839 Free PMC article. Review.
Gender inclusive care toolkit for hospitals.
Dhillon G, Grewal H, Monga V, Munjal R, Buddhavarapu VS, Verma RK, Sharma P, Kashyap R. Dhillon G, et al. Among authors: monga v. Lancet Reg Health Am. 2023 Sep 3;26:100583. doi: 10.1016/j.lana.2023.100583. eCollection 2023 Oct. Lancet Reg Health Am. 2023. PMID: 37876668 Free PMC article. No abstract available.
Alliance A071401: Phase II Trial of Focal Adhesion Kinase Inhibition in Meningiomas With Somatic NF2 Mutations.
Brastianos PK, Twohy EL, Gerstner ER, Kaufmann TJ, Iafrate AJ, Lennerz J, Jeyapalan S, Piccioni DE, Monga V, Fadul CE, Schiff D, Taylor JW, Chowdhary SA, Bettegowda C, Ansstas G, De La Fuente M, Anderson MD, Shonka N, Damek D, Carrillo J, Kunschner-Ronan LJ, Chaudhary R, Jaeckle KA, Senecal FM, Kaley T, Morrison T, Thomas AA, Welch MR, Iwamoto F, Cachia D, Cohen AL, Vora S, Knopp M, Dunn IF, Kumthekar P, Sarkaria J, Geyer S, Carrero XW, Martinez-Lage M, Cahill DP, Brown PD, Giannini C, Santagata S, Barker FG 2nd, Galanis E. Brastianos PK, et al. Among authors: monga v. J Clin Oncol. 2023 Jan 20;41(3):618-628. doi: 10.1200/JCO.21.02371. Epub 2022 Oct 26. J Clin Oncol. 2023. PMID: 36288512 Free PMC article. Clinical Trial.
166 results